Request for emergency use authorization for use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients, Food, U. and Drug Administration, available at <https://www.fda.gov/media/137564/download> (last visited May 1, 2020).+(last+visited+May+1,+2020).>Google Scholar

Wang, M., Cao, R., Zhang, L., Yang, X., et al., “Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019- nCoV) in vitro,” Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019- nCoV) in vitro, 30, no. 3 (2020): 269–271.Google Scholar

Beigel, J.H., Tomashek, K.M., L.Dodd, E., et al., “Remdesivir for the Treatment of Covid-19 - Preliminary Report,” New England Journal of Medicine (2020) (E-pub ahead of print).Google Scholar

HHS announces shipments of donated remdesivir for hospitalized patients with COVID-19, U.S. Department of Health & Human Services, available at <https://www.hhs.gov/about/news/2020/05/09/hhs-ships-firstdoses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html> (last visited May 25, 2020).+(last+visited+May+25,+2020).>Google Scholar

Hill, A., Wang, J., Levi, J., Heath, K., and Fortunak, J., “Minimum Costs to Manufacture New Treatments for COVID- 19,” Minimum Costs to Manufacture New Treatments for COVID- 19, 6, no. 2 (2020): 61–69.Google Scholar

Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19, Institute for Clinical and Economic Review (ICER), available at <https://icer-review.org/wp-content/uploads/2020/05/ICER-COVID_Initial_Abstract_05012020-3.pdf> (last visited May 25, 2020).+(last+visited+May+25,+2020).>Google Scholar

Provides, I.E. First Update to Pricing Models for Remdesivir as a Treatment for COVID-19, Institute for Clinical and Economic Review (ICER), available at <https://icer-review.org/announcements/updated_icer-covid_models_june_24/> (last visited June 30, 2020).+(last+visited+June+30,+2020).>Google Scholar

“Remdesivir, the First Coronavirus Drug, Gets a Price Tag,” The New York Times, available at <https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.html> (last visited June 30, 2020).+(last+visited+June+30,+2020).>Google Scholar

Antiviral Compound Provides Full Protection from Ebola Virus in Nonhuman Primates, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), available at <https://www.usamriid.army.mil/press_releases/Travis%20ID%20Week%20FINAL.pdf> (last visited April 11, 2020); Siegel, D., H.Hui, C., Doerffler, E., M.Clarke, O., et al., “Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f ][triazin- 4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses,” Journal of Medicinal Chemistry 60, no. 5 (2017): 1648–1661.CrossRefGoogle Scholar

Siegel, supra note 9.Google Scholar

Siegel, supra note 9; T.Warren, K., Jordan, R., M.Lo, K., et al., “Therapeutic Efficacy of the Small Molecule GS-5734 Against Ebola Virus in Rhesus Monkeys,” Nature 531, no. 7594 (2016): 381–385. (published correction appears in ACS Chemical Biology 11, no. 5 (2016):1463).CrossRefGoogle ScholarPubMed

Siegel, supra note 9.Google Scholar

Koplon, S., “Investigational compound remdesivir, developed by UAB and researchers, NI., being used for treatment of novel coronavirus,” News, UA., available at <https://www.uab.edu/news/health/item/11082-investigational-compoundremdesivir-developed-by-uab-and-nihresearchers-being-used-for-treatmentof-novel-coronavirus> (last visited April 11, 2020).+(last+visited+April+11,+2020).>Google Scholar

Sheahan, T.P., Sims, A.C., R.Graham, L., et al., “Broad-spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses,” Science Translational Medicine 9, no. 396 (2017): eaal3653; M.Agostini, L., E.Andres, L., A.Sims, C., et al., “Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease,” mBio 9, no. 2 (2018): e00221-18.CrossRefGoogle ScholarPubMed

Sheahan, T.P., Sims, A.C., S.Leist, R., et al., “Comparative Therapeutic Efficacy of remdesivir and Combination lopinavir, ritonavir, and interferon beta against MERS-CoV,” Nature Communications 11, no. 1 (2020): 222.CrossRefGoogle ScholarPubMed

Role of the Federal Government in the Development of Remdesivir, Knowledge Ecology International, available at <https://www.keionline.org/wpcontent/uploads/KEI-Briefing-Note-2020_1GS-5734-Remdesivir.pdf> (last visited March 23, 2020).+(last+visited+March+23,+2020).>Google Scholar

GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen, ClinicalTrials.gov, available at <https://clinicaltrials.gov/ct2/show/NCT02818582> (last visited June 3, 2020).+(last+visited+June+3,+2020).>Google Scholar

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease, ClinicalTrials.gov, available at <https://clinicaltrials.gov/ct2/show/NCT03719586> (last visited June 3, 2020); Mulangu, S., L.Dodd, E., R.Davey, T., O.Mbaya, T., et al., “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics, 381, no. 24 (2019): 2293–2303.Google Scholar

Joseph, A., “As the Coronavirus Spreads, a Drug that Once Raised the World's Hopes is Given a Second Shot,” Stat News, available at <https://www.statnews.com/2020/03/16/remdesivirsurges-ahead-against-coronavirus/?utm_content=buffer8f626&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic.> (last visited April 11, 2020). (last visited April 11, 2020).' href=https://scholar.google.com/scholar?q=Joseph,+A.,+“As+the+Coronavirus+Spreads,+a+Drug+that+Once+Raised+the+World's+Hopes+is+Given+a+Second+Shot,”+Stat+News,+available+at++(last+visited+April+11,+2020).>Google Scholar

Cohen, J., “Chinese Researchers Reveal Draft Genome of Virus Implicated in Wuhan Pneumonia Outbreak,” American Association for the Advancement of Science, available at <https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genomevirus-implicated-wuhan-pneumoniaoutbreak> (last visited June 3, 2020).+(last+visited+June+3,+2020).>Google Scholar

Morse, J.S., Lalonde, T., Xu, S., and Liu, W.R., “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019- nCoV,” Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019- nCoV, 21, no. 5 (2020): 730–738; W.Zhang, F., Stephen, P., J.Theriault, F., Wang, R., S.Lin, X., “Novel Coronavirus Polymerase and Nucleotidyl- Transferase Structures: Potential to Target New Outbreaks,” Journal of Physical Chemistry Letters 11 (2020):4430-4435.Google Scholar

Wang et al., supra note 2.Google Scholar

E. de Wit, Feldmann, F., Cronin, J., et al., “Prophylactic and Therapeutic Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of MERS-CoV Infection,” Prophylactic and Therapeutic Remdesivir (GS-5734) Treatment in the Rhesus Macaque Model of MERS-CoV Infection, 117, no. 2 (2020): 6771–6776; C.Gordon, J., E.Tchesnokov, P., J.Feng, Y., D.Porter, P., and Gotte, M., “The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus,” Journal of Biological Chemistry 295, no. 15 (2020): 4773-4779.Google Scholar

de Wit, supra note 23.Google Scholar

Wang, Y., Zhang, D., Du, G., et al., “Remdesivir in Adults with Severe COVID- 19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial,” Lancet 395, no. 10236 (2020):1569- 1578. (Published correction appears in Lancet, 395, no. 10238 (2020):1694).Google Scholar

Grein, J., Ohmagari, N., Shin, D., et al., “Compassionate Use of Remdesivir for Patients with Severe Covid-19,” New England Journal of Medicine (2020) (E-pub ahead of print).Google Scholar

Beigel, supra note 3.Google Scholar

Supra note 16.Google Scholar

Search Orphan Drug Designations and Approvals, U.Food, S. and Drug Administration (FDA), available at <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=490515> (last visited April 11, 2020).+(last+visited+April+11,+2020).>Google Scholar

Fang, L. and Lerner, S., “Coronavirus Treatment Developed by Gilead Sciences Granted ‘Rare Disease’ Status, Potentially Limiting Affordability,” The Intercept, available at <https://theintercept.com/2020/03/23/gilead-sciences-coronavirus-treatment-orphandrugstatus/> (last visited April 11, 2020).+(last+visited+April+11,+2020).>Google Scholar

FDA gives Gilead a seven year regulatory monopoly for remdesivir to treat COVID-19, on grounds it is an “Orphan” treating a rare disease, Knowledge Ecology International, available at <https://www.keionline.org/32546> (last visited March 23, 2020).+(last+visited+March+23,+2020).>Google Scholar

Hemel, D. and Ouellette, L.L., “Pharmaceutical Profits and Public Health Are Not Incompatible,” New York Times, available at <https://www.nytimes.com/2020/04/08/opinion/coronavirus-drug-company-profits.html> (last visited April 11, 2020).+(last+visited+April+11,+2020).>Google Scholar

Sanders Calls on Trump to Rescind Pharma Giveaway of Potential Coronavirus Treatment, The Official U.S. Senate website of Senator Bernie Sanders of Vermont, available at <https://www.sanders.senate.gov/newsroom/press-releases/sanders-calls-on-trumpto-rescind-pharma-giveaway-of-potential-coronavirus-treatment> (last visited April 11, 2020); Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation, Gilead Company Statements, available at <https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-requestto-rescind-remdesivir-orphan-drugdesignation> (last visited April 11, 2020).+(last+visited+April+11,+2020);+Gilead+Sciences+Statement+on+Request+to+Rescind+Remdesivir+Orphan+Drug+Designation,+Gilead+Company+Statements,+available+at++(last+visited+April+11,+2020).>Google Scholar

Sheahan 2017, supra note 14; Supra note 14; Sheahan 2020, supra note 15.Google Scholar

Supra note 16.Google Scholar

Supra note 16.Google Scholar